Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Blood
Frederik DammGroupe Francophone des Myélodysplasies

Abstract

A cohort of MDS patients was examined for mutations affecting 4 splice genes (SF3B1, SRSF2, ZRSR2, and U2AF35) and evaluated in the context of clinical and molecular markers. Splice gene mutations were detected in 95 of 221 patients. These mutations were mutually exclusive and less likely to occur in patients with complex cytogenetics or TP53 mutations. SF3B1(mut) patients presented with lower hemoglobin levels, increased WBC and platelet counts, and were more likely to have DNMT3A mutations. SRSF2(mut) patients clustered in RAEB-1 and RAEB-2 subtypes and exhibited pronounced thrombocytopenias. ZRSR2(mut) patients clustered in International Prognostic Scoring System intermediate-1 and intermediate-2 risk groups, had higher percentages of bone marrow blasts, and more often displayed isolated neutropenias. SRSF2 and ZRSR2 mutations were more common in TET2(mut) patients. U2AF35(mut) patients had an increased prevalence of chromosome 20 deletions and ASXL1 mutations. Multivariate analysis revealed an inferior overall survival and a higher AML transformation rate for the genotype ZRSR2(mut)/TET2(wt) (overall survival: hazard ratio = 3.3; 95% CI, 1.4-7.7; P = .006; AML transformation: hazard ratio = 3.6; 95% CI, 2-4.2; P = .026). Ou...Continue Reading

References

Jan 15, 2009·Journal of Internal Medicine·M Jädersten, E Hellström-Lindberg
Feb 26, 2009·Cell·Markus C WahlReinhard Lührmann
Apr 25, 2009·British Journal of Haematology·Véronique Gelsi-BoyerDaniel Birnbaum
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Jun 2, 2009·Nature Genetics·Saskia M C LangemeijerJoop H Jansen
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Jul 6, 2010·Nature Genetics·Thomas ErnstNicholas C P Cross
Oct 1, 2010·British Journal of Haematology·Véronique Gelsi-BoyerDaniel Birnbaum
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Mar 19, 2011·Leukemia·M J WalterT A Graubert
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholArnold Ganser
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholMichael Heuser
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Sep 13, 2011·Nature·Kenichi YoshidaSeishi Ogawa
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Oct 15, 2011·Blood·Luca MalcovatiUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per l
Nov 8, 2011·Haematologica·Marta PratcoronaPeter J M Valk
Dec 14, 2011·Nature Genetics·Timothy A GraubertMatthew J Walter
Jan 6, 2012·The New England Journal of Medicine·Lucile CouronnéOlivier A Bernard

❮ Previous
Next ❯

Citations

Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Oct 12, 2012·International Journal of Hematology·Seishi Ogawa
Jan 30, 2013·International Journal of Hematology·Tomoki Naoe, Hitoshi Kiyoi
Apr 6, 2013·Leukemia·R Itzykson, E Solary
Nov 24, 2012·Nature Reviews. Cancer·Azra Raza, Naomi Galili
Nov 6, 2012·Nature Reviews. Drug Discovery·Sophie BonnalJuan Valcárcel
Feb 9, 2013·Genetic Testing and Molecular Biomarkers·Jing YangYu-Juan Ma
Jul 25, 2012·BMC Cancer·Anne MuratiDaniel Birnbaum
Mar 23, 2012·Journal of Hematology & Oncology·Véronique Gelsi-BoyerDaniel Birnbaum
Feb 11, 2014·Best Practice & Research. Clinical Haematology·Luca Malcovati, Mario Cazzola
Jan 21, 2014·Bioinformatics·Moritz GerstungPeter J Campbell
Feb 12, 2013·Clinical Biochemistry·Jing YangXing-xing Chen
Jul 30, 2014·Hematology/oncology Clinics of North America·Sylvia S Bottomley, Mark D Fleming
Oct 15, 2014·Seminars in Hematology·Ashley M Perry, Eyal C Attar
Nov 4, 2015·Biomolecules·Lulzim Shkreta, Benoit Chabot
Jul 6, 2014·Expert Opinion on Pharmacotherapy·Massimo BrecciaGiuliana Alimena
Dec 3, 2015·Blood·Virginie ChesnaisUNKNOWN Groupe Francophone des Myélodysplasies
Dec 17, 2014·Expert Opinion on Drug Metabolism & Toxicology·Anna WojtuszkiewiczJacqueline Cloos
Jan 31, 2016·Current Opinion in Hematology·Stephen S Chung
Jul 11, 2013·Critical Reviews in Oncology/hematology·Valeria SantiniGhulam Mufti
Mar 5, 2016·Surgical Pathology Clinics·Valentina Nardi, Robert P Hasserjian
Mar 5, 2016·International Journal of Hematology·Hamza CelikGrant A Challen
Oct 11, 2012·International Journal of Cancer. Journal International Du Cancer·June Li
Jul 23, 2013·British Journal of Haematology·Austin G KulasekararajGhulam J Mufti
Jun 7, 2014·British Journal of Haematology·Guillermo Montalbán BravoGuillermo García-Manero
Apr 12, 2014·American Journal of Hematology·Chien-Chin LinHwei-Fang Tien
Jan 30, 2014·Cancer·Brian S White, John F DiPersio
Feb 14, 2014·Wiley Interdisciplinary Reviews. RNA·Kenichi Yoshida, Seishi Ogawa
Dec 17, 2014·Immunological Reviews·Christopher N HahnDevendra K Hiwase

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Blood
Luca MalcovatiChronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per l
The New England Journal of Medicine
Elli PapaemmanuilChronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
© 2022 Meta ULC. All rights reserved